To Market Qsymia, Vivus Takes On Additional Debt
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of the weight-loss drug haven’t been brisk, but Vivus can fortify its balance sheet with up to $110 million in debt. Analysts say it could raise more soon, provided it gains a regulatory victory.